若生智能
Drug Database
AN

antithrombin III (Atenotiv / ATenativ / ATnativ)

✓ Approved

Pfizer, Inc. · SERPINC1 · 细胞治疗

什么是 antithrombin III？

antithrombin III 是一种细胞治疗，由Pfizer, Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Atenotiv, ATenativ, ATnativ
公司Pfizer, Inc.
药物类别细胞治疗
分子靶点SERPINC1
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Pfizer, Inc.

作用机制

分子靶点

antithrombin III 作用于 1 个分子靶点：

SERPINC1serpin family C member 1 (ATIII, AT3D)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

antithrombin III 针对 3 个适应症，涉及 3 个治疗领域。

治疗领域疾病/病症分期
Congenital, familial and genetic disordersAntithrombin III deficiency✓ Approved
Vascular disordersThrombosis✓ Approved
Surgical and medical proceduresAdjuvant therapy✓ Approved

相关研究文献

PubMedCarbohydrate polymers2026-06-13

Structural characterization, in vitro anticoagulant, and antiplatelet activities of a Distolasterias nipon dermatan sulfate-like polymer with a distinctive sulfation pattern.

Filshtein Alina P AP, Belova Vlada S VS, Taran Ilya V IV, Kokoulin Maxim S MS

A novel dermatan sulfate-like polysaccharide (DNP) was isolated from the body walls of the starfish Distolasterias nipon. Its structure was elucidated using chemical methods and 2D NMR spectroscopy, revealing a backbone of →4)-α-L-IdopA-(1→3)-β-D-GalpNAc-(1→, with the α-L-iduronic acid residues predominantly 2,3-di-O-sulfated, alongside 2-O- and 3-O-monosulfated variants, and the β-D-GalpNAc residues 4-O-sulfated. Functional assays showed that DNP prolongs thrombin time (TT) comparable to heparin and more potently than enoxaparin (Clexane®), whereas its effect on activated partial thromboplastin time (APTT) is less pronounced. The anticoagulant activity of DNP is characterized by antithrombin-dependent thrombin inhibition and moderate suppression of factor Xa. Furthermore, the polysaccharide does not induce platelet aggregation nor interfere with physiological ADP-mediated pathways, but it inhibits ristocetin-induced aggregation. These findings identify D. nipon as a source of a dermatan sulfate structurally distinct from those found in other starfishes and invertebrates, and characterized by an antithrombin-dependent anti-IIa/anti-Xa profile and additional antiplatelet properties.

PMID 42285676
阅读全文 →
PubMedJournal of reproductive immunology2026-06-13

Efficacy of combined low-molecular-weight heparin and low-dose aspirin therapy versus aspirin alone in women with thrombophilia-related recurrent pregnancy loss: A retrospective cohort study.

Kim Hyun Mi HM, Jang Won-Kyu WK, Lee Jisun J, Kim Dong Ja DJ et al.

The role of inherited thrombophilia (IT) in recurrent pregnancy loss (RPL) remains uncertain, unlike established antiphospholipid antibodies (APA). This study evaluated pregnancy outcomes in APA and IT patients, comparing low-molecular-weight heparin (LMWH) plus low-dose aspirin (LDA) versus LDA alone in IT. After excluding genetic, anatomical, and endocrinologic causes, 227 women with RPL related to APA or IT such as protein C, protein S, and antithrombin III deficiencies, factor V Leiden, or prothrombin gene mutations were enrolled. All women with thrombotic causes were taking LDA before pregnancy. LMWH was added after a positive pregnancy test in women with APA, and women with IT received either LMWH plus LDA or LDA alone. Pregnancy outcomes and miscarriage rates were compared by etiology and treatment. The APA group had significantly higher miscarriage rates than IT group (30.4% vs. 14.8%, p = 0.024) despite LMWH + LDA treatment. Within the IT group (106 LDA-only, 54 LMWH+LDA), miscarriage and full-term birth rates were similar, but early preterm birth < 34 weeks was significantly lower with LMWH + LDA treatment (p = 0.045). Women with APA-related RPL had worse outcomes than IT patients despite LMWH and LDA treatment. In IT-associated RPL, adding LMWH to LDA may not prevent miscarriage but could reduce early preterm birth risk.

PMID 42284852
阅读全文 →
PubMedJournal of hazardous materials2026-06-13

Iron ores with contrasting redox properties drive iron biogeochemical cycling to enhance acesulfame and nutrients removal in constructed wetlands.

Li Mingjun M, Lin Zhiyi Z, Yan Peihao P, Lan Tianzhi T et al.

Iron minerals have attracted considerable attention for their potential to enhance the removal of nutrients and emerging contaminants within water treatment. However, how the intrinsic redox state of iron in minerals governs pollutant attenuation remains insufficiently understood. In this study, Fe(III) (hematite) and Fe(II) minerals (pyrite) were employed to construct constructed wetlands (CWs) for the simultaneous removal of the artificial sweetener acesulfame (ACE) and nutrients. According to substrate characterization and soluble iron monitoring, the observed elemental changes indicated the occurrence of Fe(III)/Fe(II) cycling and its involvement in the removal of ACE and nutrients. Moreover, the Fe(III)-based CWs exhibited markedly higher iron redox activity than Fe(II)-based CWs. Correspondingly, Fe(III)-based CWs achieved higher removal performance of pollutants than Fe(II)-based CWs, with average removal efficiencies of 32.3% for total nitrogen, 88.7% for total phosphorus, and 44.8% for acesulfame, respectively. Simultaneously, Fe(III) minerals promoted the formation of iron plaque on roots, suggesting enhanced iron cycling in the rhizosphere. Microbial community analysis further revealed diverse communities associated with iron transformation, including 13 genera capable of Fe(II) oxidation and 43 genera involved in dissimilatory iron reduction in both substrates and rhizosphere zones. These taxa mediated electron transfer processes that linked iron redox transitions with pollutant transformation. Moreover, the intrinsic redox state of iron minerals established the contrasting electron-flow regimes during iron cycling. This work provides new insight into the role of iron cycling in pollutant removal as an endogenous metabolic driver.

PMID 42284775
阅读全文 →
PubMedBMC pulmonary medicine2026-06-13

Predictive value of critical illness scores for outcomes of patients with community-acquired pneumonia: analysis of critical care data from the MIMIC-IV database.

Wang Yao-Tung YT, Huang Yuan-Fu YF

This study evaluated the predictive abilities of critical illness scoring instruments in intensive care unit (ICU) patients with community-acquired pneumonia. In this population-based retrospective study, patients with community-acquired pneumonia admitted to the ICU were extracted from the fourth edition of the Medical Information Mart for Critical Care (MIMIC IV) database from 2008 to 2019. Critical illness scores used were the Simplified Acute Physiologic Score II (SAPS II), Acute Physiology and Chronic Health Evaluation III (APACHE III), Sequential organ failure assessment (SOFA), Oxford Acute Severity of Illness Score (OASIS), and logistic organ dysfunction score (LODS), CURB-65, and CHA2DS2-VASc scoring systems. Patients' mean age was 65.1 years, 56.7% were male, 66.1% were white, and 53.8% were admitted to the ICU from the emergency department. All seven critical illness scores were significantly higher in non-survivor patients who had cardiovascular events and those who developed atrial fibrillation than in those who did not. APACHE III (AUROC 0.761) and LODS (0.742) showed relatively higher AUROCs for predicting 90-day mortality than the other evaluated scores, although their discrimination remained fair. For predicting incident atrial fibrillation, CURB-65 (0.672), CHA₂DS₂-VASc (0.655), and APACHE III (0.625) had AUROCs above 0.6, indicating modest discrimination. APACHE III and LODS showed relatively higher, but still fair, discrimination for 90-day mortality compared with the other evaluated scores. All scores demonstrated poor discrimination for incident cardiovascular events. CURB-65 and CHA₂DS₂-VASc showed relatively higher but modest discrimination for incident atrial fibrillation, suggesting limited utility as stand-alone predictive tools.

PMID 42286540
阅读全文 →
PubMedCarbohydrate polymers2026-06-13

Molecular engineering of cellulose-rich Caragana fiber with phytic acid construct high-energy phosphate sites for efficient rare earth capture.

Wang Xiaoxia X, Zhang Huan H, Liu Xiangyu X, Zhao Qile Q et al.

Sustainable recovery of rare earth elements (REEs) by adsorption faces an inherent trade-off among capacity, kinetics, and stability. We report a molecular engineering strategy that converts Caragana fiber (CF), a cellulose-rich waste biomass, into a hierarchical adsorbent (PA-CF) using naturally derived phytic acid (PA). PA acts as a green catalyst that restructures the cellulose matrix and a grafting agent that introduces abundant high-energy phosphate binding sites. In this design, phosphate groups distribute throughout a covalently integrated network instead of on external or pore surfaces, mitigating interfacial limitations of conventional heterogeneous adsorbents. Under optimized conditions, PA-CF achieves adsorption capacities of 224.22 mg/g for La(III), 262.47 mg/g for Gd(III), and 327.87 mg/g for Lu(III). Site energy distribution analysis confirms that high-energy sites (∼40 kJ/mol) dominate adsorption and provides a thermodynamic basis for understanding phosphate-REE binding. The adsorbent performs reliably in complex matrices (seawater, tap water) and tolerates competing ions (Na+, Mg2+, Zn2+, Al3+, Fe3+). It retains >70% of initial capacity after five cycles. Mechanistic studies indicate adsorption proceeds mainly through chemical complexation and electrostatic interactions. These results show PA restructures cellulose into a covalently integrated network rather than surface-grafted ones, offering a transferable strategy for designing advanced carbohydrate-based materials for resource recovery.

PMID 42285664
阅读全文 →
PubMedExpert opinion on investigational drugs2026-06-13

Odronextamab: a bispecific antibody for follicular lymphoma.

Garcia-Sancho Alejandro Martín AM, Cabero-Martínez Almudena A, Gutierrez Norma C NC

Follicular lymphoma (FL) is an indolent lymphoma characterized by repeated relapses and progressively shorter responses with successive lines of therapy, particularly in patients with early progression (POD24). Although chemoimmunotherapy has historically dominated treatment, the therapeutic landscape has shifted toward chemo-free approaches. T-cell - redirecting therapies, including bispecific antibodies, have demonstrated high efficacy in relapsed/refractory (R/R) FL. This review discusses the role of odronextamab in FL, including its mechanism of action, pharmacokinetic properties, and key clinical efficacy and safety data from the ELM-1 and ELM-2 trials, which supported its approval by the European Medicines Agency (EMA). Future development strategies are also reviewed, including combinations with other agents and use in earlier lines of therapy, including the frontline setting, as investigated in the phase III OLYMPIA-1, OLYMPIA-2, and OLYMPIA-5 studies. Odronextamab has shown highly promising single-agent activity in R/R FL. Although its efficacy and safety appear broadly comparable to those of mosunetuzumab and epcoritamab, differences in treatment duration, route of administration, dosing frequency, and cytokine release syndrome prophylaxis may influence treatment selection. Ongoing phase III studies may further define its role across the FL treatment continuum.

PMID 42287116
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多antithrombin III